Article
Clinical prospects of WRN inhibition as a treatment for MSI tumours
15 Nov 2022
Abstract excerpt
The discovery of synthetic lethal interactions with genetic deficiencies in cancers has highlighted several candidate targets for drug development, with variable clinical success. Recent work has unveiled a promising synthetic lethal interaction between inactivation/inhibition of the WRN DNA helicase and tumours with microsatellite instability, a phenotype that arises from DNA mismatch repair deficiency. While...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
